Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09 Febbraio 2022 - 1:30PM
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology
platform company developing universally implantable bioengineered
human tissue at commercial scale, today announced that Laura
Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander,
Chief Financial Officer, will participate in a virtual fireside
chat at the BTIG MedTech, Digital Health, Life Science &
Diagnostic Tools Conference on Feb. 15, 2022, at 9 a.m. EST.
The webcast will be available for replay for at least 30 days
following the presentation
at https://humacyte.gcs-web.com/news-events/events-and-presentations.
About HumacyteHumacyte, Inc. (Nasdaq: HUMA) is
developing a disruptive biotechnology platform to deliver
universally implantable bioengineered human tissues and organs
designed to improve the lives of patients and transform the
practice of medicine. The Company develops and manufactures
acellular tissues to treat a wide range of diseases, injuries and
chronic conditions. Humacyte’s initial opportunity, a portfolio of
human acellular vessels (HAVs), is currently in late-stage clinical
trials targeting multiple vascular applications, including vascular
trauma repair, arteriovenous access for hemodialysis, and
peripheral arterial disease. Preclinical development is also
underway in coronary artery bypass grafts, pediatric heart surgery,
treatment of type 1 diabetes, and multiple novel cell and tissue
applications. Humacyte’s 6mm HAVs for AV access for performing
hemodialysis was the first product candidate to receive the FDA’s
Regenerative Medicine Advanced Therapy (RMAT) expedited review
designation, and the HAV technology received priority designation
for the treatment of vascular trauma by the U.S. Secretary of
Defense. For more information, visit www.Humacyte.com.
Humacyte Investor
Contact:investors@humacyte.com
Humacyte Media Contact:media@humacyte.com
Grafico Azioni Humacyte (NASDAQ:HUMA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Humacyte (NASDAQ:HUMA)
Storico
Da Set 2023 a Set 2024